Cara Therapeutics Financial Statements (CARA)
|
|
|
|
Report date
|
|
|
25.02.2021 |
01.03.2022 |
06.03.2023 |
31.12.2023 |
06.03.2024 |
|
14.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
135.1 |
23.0 |
41.9 |
21.0 |
21.0 |
|
8.69 |
|
Operating Income, bln rub |
|
|
5.39 |
-89.1 |
-87.5 |
-121.5 |
-121.5 |
|
-82.1 |
|
EBITDA, bln rub |
? |
|
5.59 |
-88.2 |
-83.8 |
-121.5 |
-117.7 |
|
-88.8 |
|
Net profit, bln rub |
? |
|
8.41 |
-88.2 |
-83.4 |
-118.5 |
-118.5 |
|
-95.5 |
|
|
OCF, bln rub |
? |
|
-5.49 |
-60.1 |
-78.7 |
|
-92.1 |
|
-74.2 |
|
CAPEX, bln rub |
? |
|
0.349 |
0.039 |
0.043 |
|
2.38 |
|
3.10 |
|
FCF, bln rub |
? |
|
-5.84 |
-60.1 |
-78.8 |
|
-94.5 |
|
-77.3 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
|
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
129.7 |
112.1 |
122.1 |
136.3 |
142.5 |
|
90.5 |
|
Cost of production, bln rub |
|
|
107.1 |
1.55 |
7.27 |
6.17 |
6.17 |
|
1.35 |
|
R&D, bln rub |
|
|
107.9 |
82.7 |
91.9 |
108.5 |
108.5 |
|
61.0 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.604 |
0.604 |
|
6.46 |
|
|
Assets, bln rub |
|
|
271.2 |
247.1 |
182.2 |
125.8 |
125.8 |
|
51.3 |
|
Net Assets, bln rub |
? |
|
249.0 |
227.5 |
158.8 |
57.1 |
57.1 |
|
0.707 |
|
Debt, bln rub |
|
|
5.28 |
3.67 |
1.92 |
43.2 |
43.2 |
|
3.42 |
|
Cash, bln rub |
|
|
180.9 |
167.0 |
145.4 |
100.8 |
100.8 |
|
42.0 |
|
Net debt, bln rub |
|
|
-175.7 |
-163.4 |
-143.5 |
-57.6 |
-57.6 |
|
-38.6 |
|
|
Ordinary share price, rub |
|
|
15.1 |
12.2 |
10.7 |
0.743 |
0.743 |
|
1.18 |
|
Number of ordinary shares, mln |
|
|
47.4 |
50.7 |
53.7 |
54.1 |
54.1 |
|
54.8 |
|
|
Market cap, bln rub |
|
|
717 |
618 |
576 |
40 |
40 |
|
65 |
|
EV, bln rub |
? |
|
542 |
454 |
433 |
-17 |
-17 |
|
26 |
|
Book value, bln rub |
|
|
249 |
228 |
159 |
57 |
57 |
|
1 |
|
|
EPS, rub |
? |
|
0.18 |
-1.74 |
-1.55 |
-2.19 |
-2.19 |
|
-1.74 |
|
FCF/share, rub |
|
|
-0.12 |
-1.19 |
-1.47 |
0.00 |
-1.74 |
|
-1.41 |
|
BV/share, rub |
|
|
5.25 |
4.49 |
2.96 |
1.05 |
1.05 |
|
0.01 |
|
|
EBITDA margin, % |
? |
|
4.14% |
-383.0% |
-200.2% |
-579.4% |
-561.1% |
|
-1 022% |
|
Net margin, % |
? |
|
6.23% |
-383.0% |
-199.2% |
-565.2% |
-565.2% |
|
-1 100% |
|
FCF yield, % |
? |
|
-0.81% |
-9.73% |
-13.7% |
0.00% |
-234.8% |
|
-119.5% |
|
ROE, % |
? |
|
3.38% |
-38.8% |
-52.5% |
-207.6% |
-207.6% |
|
-13 511% |
|
ROA, % |
? |
|
3.10% |
-35.7% |
-45.8% |
-94.2% |
-94.2% |
|
-186.1% |
|
|
P/E |
? |
|
85.3 |
-7.00 |
-6.91 |
-0.34 |
-0.34 |
|
-0.68 |
|
P/FCF |
|
|
-122.9 |
-10.3 |
-7.32 |
|
-0.43 |
|
-0.84 |
|
P/S |
? |
|
5.31 |
26.8 |
13.8 |
1.92 |
1.92 |
|
7.45 |
|
P/BV |
? |
|
2.88 |
2.72 |
3.63 |
0.70 |
0.70 |
|
91.5 |
|
EV/EBITDA |
? |
|
96.8 |
-5.15 |
-5.16 |
0.14 |
0.15 |
|
-0.29 |
|
Debt/EBITDA |
|
|
-31.4 |
1.85 |
1.71 |
0.47 |
0.49 |
|
0.43 |
|
|
R&D/CAPEX, % |
|
|
30 903% |
212 054% |
213 672% |
|
4 569% |
|
1 969% |
|
|
CAPEX/Revenue, % |
|
|
0.26% |
0.17% |
0.10% |
0.00% |
11.3% |
|
35.7% |
|
| Cara Therapeutics shareholders |
